Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Executive VP | July 13, 2018 | July 17, 2018 |
| CytoDyn Inc.CYDY · Entity 5856 | Chief Technology Officer | November 15, 2022 | November 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date July 13, 2018 · Filed July 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2028-07-13 | Direct | 75,000 |
Reported balance
After 2018-07-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-13 · Grant · Acquired 75,000 · Balance 75,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant.
CytoDyn Inc.
Report date November 15, 2022 · Filed November 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,090 |
Reported balance
After 2022-11-15 transaction · row 1
1 source rowRow 1 · 2022-11-15 · Grant · Acquired 13,671 · Balance 500,090 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2022 Filed Nov 17, 2022 23:49 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-119978 · tm2230762-1_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,090 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:52 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 16,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-114098 · tm2228860d2_4seq.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,419 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-109693 · tm2228392-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,335 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 23:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-105983 · tm2227293-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,907 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:31 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 8,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-101254 · tm2226067-1_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,887 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 23:56 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 10,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097602 · tm2221304-9_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,922 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 6,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092175 · tm2221304-6_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,406 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 31, 2022 Filed Aug 4, 2022 20:11 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 7,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-086132 · tm2222420-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,818 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:03 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080838 · tm2221304-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,716 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077436 · tm2220248-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,288 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 15, 2022 Filed Jun 21, 2022 20:50 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073013 · tm2218921-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,268 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 31, 2022 Filed Jun 8, 2022 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 17,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069303 · tm2217755-3_4seq1.xml · nonDerivative · entry 5 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,597 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 15, 2022 Filed Jun 8, 2022 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 16,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069303 · tm2217755-3_4seq1.xml · nonDerivative · entry 4 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,508 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 30, 2022 Filed Jun 8, 2022 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 17,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069303 · tm2217755-3_4seq1.xml · nonDerivative · entry 3 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,424 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 15, 2022 Filed Jun 8, 2022 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 20,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069303 · tm2217755-3_4seq1.xml · nonDerivative · entry 2 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,335 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| March 31, 2022 Filed Jun 8, 2022 20:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 14,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069303 · tm2217755-3_4seq1.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,081 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000899243-21-032389 · doc4.xml · derivative · entry 3 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock · 500,000 shares Expires 2031-08-06 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning on August 6, 2022. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032389 · doc4.xml · nonDerivative · entry 2 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,301 F2 · shares: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. F2 · price: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 34,801 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032389 · doc4.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,801 F1 · shares: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. F1 · price: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:38 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 500,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001807094-20-000020 · primary_doc.xml · derivative · entry 2 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-06-15 F3 · date: The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the "Plan") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020. F4 · derivative.exercise_date: The stock option vests annually in three equal installments beginning June 15, 2021 Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:38 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000020 · primary_doc.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan. F2 · price: Not applicable. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030004 · doc4.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: 200,000 options vest immediately upon grant and 400,000 options will vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:04 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025314 · doc4.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| October 07, 2019 Filed Oct 11, 2019 01:44 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025494 · doc4a.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · shares: This report is being filed to correct an inadvertent error, to report the options issued October 7, 2019 as acquired (and not disposed of) in the transaction, in Column 5. F2 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| December 22, 2018 Filed Dec 26, 2018 23:58 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-18-031732 · doc4.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options vest in three equal annual installments commencing on November 16, 2019. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:17 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009324 · ownership.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries B Warrants · Derivative | 7,500 | $0.50 Strike: $0.70 | $3,750.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · derivative · entry 3 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries A Warrants · Derivative | 2,500 | $0.50 Strike: $0.60 | $1,250.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · derivative · entry 2 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 10,000 | $0.50 | $5,000.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 10,000 | $0.75 | $7,500.00 |
DisclosureSEC source: 0001213900-17-008246 · f4080217ray_actiniumpharm.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.